Boston Scientific Corporation (BSX) Balance Sheet

NYSE: BSXAssets, liabilities, debt and equity over 10 years.

BSX balance sheet, 2025

December 31, 2025 · U.S. dollars

$43.67B assets = $19.20B liabilities + $24.47B equity

What it owns$43.67BCash & ST investments: $2.04B (4.7%)Receivables: $2.93B (6.7%)Receivables $2.93BInventory: $2.94B (6.7%)Inventory $2.94BOther current: $879.0M (2.0%)PP&E: $4.50B (10.3%)PP&E $4.50BGoodwill & intangibles: $25.30B (57.9%)Goodwill & intangibles$25.30B · 58%Other non-current: $5.08B (11.6%)Other non-current$5.08B · 12%=How it is financed$43.67BCurrent liabilities: $5.44B (12.5%)Current liabilities$5.44B · 12%Long-term debt: $11.14B (25.5%)Long-term debt$11.14B · 26%Other LT liabilities: $2.62B (6.0%)$2.62BShareholders’ equity: $24.47B (56.0%)Shareholders’ equity$24.47B · 56%

Both columns are drawn to the same scale: what BSX owns equals what it owes plus shareholders’ equity. Hover a block for its value.

BSX financial health

Current ratio1.62
Comfortable · current assets cover current liabilities 1.62×
Debt / equity0.51
Moderate leverage · $0.51 of debt for each $1 of equity
Equity / assets55.5%
Equity-funded · of assets funded by shareholders
Cash / debt16.5%
Low cash cover · cash & short-term investments vs total debt
Goodwill & intangibles57.9%
Mostly intangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

BSX balance sheet trends, 2016–2025

Boston Scientific Corporation balance sheet trends
MetricTrendThenLatestChange
Total assets$18.10B2016$43.67B2025+10.3%/yr
Total liabilities$11.36B2016$19.20B2025+6.0%/yr
Shareholders’ equity$6.73B2016$24.23B2025+15.3%/yr
Cash & short-term investments$196.0M2016$2.04B2025+29.8%/yr
Total debt$5.48B2016$12.42B2025+9.5%/yr
Net cash (debt)−$5.29B2016−$10.37B2025−$5.1B
Working capital−$348.0M2016$3.35B2025+$3.7B
Book value per share$4.892016$16.212025+14.2%/yr
Current ratio0.9020161.622025+0.71
Debt / equity0.8120160.512025−0.30
Shares outstanding1.38B20161.49B2025+0.9%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

BSX assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

BSX liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

BSX debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

BSX balance sheet

Boston Scientific Corporation annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$2.04B$414.0M$865.0M$928.0M$1.93B$1.73B$217.0M$146.0M$188.0M$196.0M
Cash & equivalents$2.04B$414.0M$865.0M$928.0M$1.93B$1.73B$217.0M$146.0M$188.0M$196.0M
Short-term investments————————$803.0M$243.0M
Receivables$2.93B$2.56B$2.23B$1.97B$1.78B$1.53B$1.83B$1.61B$1.55B$1.47B
Inventory$2.94B$2.81B$2.48B$1.87B$1.61B$1.35B$1.58B$1.17B$1.08B$955.0M
Other current assets$879.0M$1.14B$937.0M$995.0M$1.00B$2.08B$1.07B$1.08B$1.01B$616.0M
Total current assets$8.79B$6.92B$6.51B$5.76B$6.32B$6.69B$4.70B$4.00B$3.82B$3.24B
Property, plant & equipment (net)$4.50B$3.74B$3.30B$2.83B$2.69B$2.54B$2.42B$1.78B$1.70B$1.63B
Goodwill & intangible assets$25.30B$23.77B$20.39B$18.82B$18.11B$15.87B$18.06B$14.28B$12.84B$12.56B
Long-term investments$0$555.0M$413.0M$407.0M$412.0M$918.0M$458.0M$424.0M$352.0M$347.0M
Other non-current assets$5.08B$4.40B$4.52B$4.65B$4.71B$4.76B$4.93B$506.0M$336.0M$319.0M
Total assets$43.67B$39.40B$35.14B$32.47B$32.23B$30.78B$30.57B$21.00B$19.04B$18.10B
Liabilities
Accounts payable$1.14B$960.0M$942.0M$862.0M$794.0M$513.0M$542.0M$349.0M$530.0M$447.0M
Short-term debt$389.0M$1.78B$531.0M$20.0M$261.0M$13.0M$1.42B$2.25B$1.80B$64.0M
Deferred revenue$313.0M$306.0M$266.0M$220.0M$208.0M$138.0M$144.0M$328.0M$191.0M$75.0M
Total current liabilities$5.44B$6.40B$4.93B$3.80B$4.27B$3.68B$4.87B$5.26B$5.65B$3.59B
Long-term debt$11.14B$8.97B$8.57B$8.91B$8.80B$9.13B$8.59B$4.80B$3.81B$5.42B
Lease obligations$125.0M$527.0M$395.0M$352.0M$395.0M$408.0M$282.0M$6.0M$1.0M—
Other long-term liabilities$2.62B$2.02B$2.10B$2.18B$2.53B$2.64B$3.23B$2.21B$2.56B$2.36B
Total liabilities$19.20B$17.39B$15.61B$14.90B$15.61B$15.45B$16.69B$12.27B$12.03B$11.36B
Shareholders' equity
Common stock & paid-in capital$17.0M$17.0M$17.0M$17.0M$17.0M$17.0M$16.0M$16.0M$17.18B$17.03B
Retained earnings (deficit)$5.57B$2.67B$819.0M−$750.0M−$1.39B−$2.38B−$2.25B−$6.95B−$8.39B−$8.58B
Treasury stock———−$2.25B−$2.25B−$2.25B−$1.72B−$1.72B−$1.72B−$1.72B
Accumulated other comprehensive income−$610.0M$275.0M$49.0M$269.0M$263.0M$207.0M$270.0M$33.0M−$59.0M$1.0M
Minority interest$239.0M$233.0M$248.0M$0————$0$0
Total shareholders' equity$24.23B$21.77B$19.28B$17.57B$16.62B$15.33B$13.88B$8.72B$7.01B$6.73B
Key figures
Total debt$12.42B$11.15B$9.49B$9.28B$9.45B$9.54B$10.28B$7.06B$5.62B$5.48B
Net cash (debt)−$10.37B−$10.73B−$8.63B−$8.35B−$7.53B−$7.80B−$10.06B−$6.91B−$5.43B−$5.29B
Working capital$3.35B$521.0M$1.58B$1.96B$2.04B$3.01B−$167.0M−$1.26B−$1.83B−$348.0M
Tangible book value−$1.07B−$2.00B−$1.11B−$1.25B−$1.49B−$540.0M−$4.18B−$5.56B−$5.82B−$5.83B
Book value per share$16.21$14.65$13.18$12.21$11.59$10.82$9.84$6.23$5.03$4.89
Shares outstanding1.49B1.49B1.46B1.44B1.43B1.42B1.41B1.40B1.39B1.38B
Current ratio1.621.081.321.511.481.820.970.760.680.90
Quick ratio0.910.460.630.760.870.890.420.330.310.47
Debt / equity0.510.510.490.530.570.620.740.810.800.81
Equity / assets55.5%55.3%54.9%54.1%51.6%49.8%45.4%41.6%36.8%37.2%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 17, 2026); data from EODHD.

BSX financial position

At the end of fiscal 2025 (December 31, 2025), Boston Scientific had total assets of $43.7 billion (up 10.9% from a year earlier), total liabilities of $19.2 billion and shareholders' equity of $24.2 billion. It held $2.0 billion in cash and short-term investments against $12.4 billion of debt, net debt of $10.4 billion. Its current ratio was 1.62. In the latest quarter (ended June 30, 2026) total assets were $45.2 billion and equity $24.9 billion.

Related: BSX income statement, BSX cash flow statement, BSX key metrics. See the BSX stock overview for the latest quote and news.

BSX balance sheet FAQ

What are Boston Scientific's total assets?

Boston Scientific reported total assets of $43.7 billion at the end of fiscal 2025 (December 31, 2025), compared with $39.4 billion a year earlier.

How much debt does Boston Scientific have?

Boston Scientific had $12.4 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.51.

How much cash does Boston Scientific have?

Boston Scientific held $2.0 billion in cash and short-term investments at the end of fiscal 2025; with $12.4 billion of debt that is net debt of $10.4 billion.

What is Boston Scientific's book value?

Boston Scientific's shareholders' equity (book value) was $24.2 billion at the end of fiscal 2025, or $16.21 per share.

What is Boston Scientific's current ratio?

Boston Scientific had current assets of $8.8 billion and current liabilities of $5.4 billion, a current ratio of 1.62 (it can cover its short-term obligations).

How much goodwill does Boston Scientific have?

Boston Scientific carried $25.3 billion of goodwill and intangible assets, 57.9% of total assets, at the end of fiscal 2025.

Medical Devices: balance sheet